17 results about "Telangiectasia" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The present application relates to a drug or pharmaceutical composition for preventing, alleviating, or treating cancer and a use thereof, as well as a method for preventing, alleviating, or treating cancer. The drug or pharmaceutical composition of the present application is capable of interfering with ataxia-telangiectasia mutated and Rad3-related kinase (ATR) and mammalian target of rapamycin (mTOR) activity, causing inactivation or reduced activity of ATR and mTOR. The present application provides a novel dual-target strategy for the treatment of cancer.

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

The invention relates to a small transcranial magnetic stimulation positioning device and method based on remote control, and the device comprises a helmet, a control host, and a medical control host. A detection space is arranged in the helmet, a camera module and a three-axis moving module are arranged in the detection space, and a positioning unit and an angle adjusting module are arranged at the movable end of the three-axis moving module; the positioning unit comprises a mounting plate, guide sleeves are vertically arranged at four corners of the lower surface of the mounting plate, guide columns are slidably arranged on the guide sleeves in a penetrating manner, and a treatment coil is arranged on the lower surface of the mounting plate; the cost can be greatly reduced, and meanwhile, the method can be well implemented; the four pressure sensors not only can detect the head shape, but also can be directly associated with the treatment coil in hardware, the position of the treatment coil can be accurately and directly obtained, and meanwhile angle adjustment and height adjustment of the treatment coil can be conducted according to needs. By means of the device, continuous treatment of the erythema rosacea can be conveniently conducted on a patient at home.

Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of Ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and methods of their preparation and use.

The application discloses a kit for constructing an ATM gene mutation ataxia-telangiectasia model pig nuclear transfer donor cell. The application provides a kit comprising ATM-gRNA1 shown in SEQ ID NO: 16, ATM-gRNA4 shown in SEQ ID NO: 17 and NCN protein. The application also provides a method for preparing a recombinant cell: co-transfecting a pig cell with ATM-gRNA1, ATM-gRNA4 and NCN protein to obtain a recombinant cell. The recombinant cell is a recombinant cell with ATM gene mutation. The kit is used for: preparing a recombinant cell; preparing an ataxia-telangiectasia model pig; preparing an ataxia-telangiectasia cell model or an ataxia-telangiectasia tissue model or an ataxia-telangiectasia organ model. The application has great application value for research and development of ataxia-telangiectasia drugs and revealing the pathogenesis of the disease.

This invention provides a protein comprising the amino acid sequence shown in SEQ ID NO: 3, 4, or 6. In some embodiments, the protein is FHTFF1.5 activator. The protein of this invention may inhibit angiogenesis by inhibiting the proliferation and migration of vascular endothelial cells; the recombinant protein may also combat telangiectasia under the skin and inhibit blood supply to tumor cells. This invention also provides the encoding nucleic acid of the protein, a vector, cells containing the protein, and its uses as innovative biomaterials in the fields of medical devices, biomedicine, and anti-aging.

The present invention discloses the use of a plant extract containing geniposide in inhibiting and / or improving angiogenesis, as well as the use of a plant extract containing geniposide in preparing a cosmetic having the efficacy of inhibiting and / or improving angiogenesis, and provides a cosmetic containing a plant extract containing geniposide and a method for inhibiting and / or improving angiogenesis. By adopting the technical solution provided by the present invention, angiogenesis in the skin can be inhibited and / or improved, thereby improving problems such as telangiectasia, skin erythema, dark circles under the eyes, etc. caused by angiogenesis.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

The invention provides a preparation method and application of a platycodon grandiflorum oil fermentation product, and the preparation method comprises the following steps: adding a proper amount of clear water into platycodon grandiflorum for soaking and cleaning, drying at low temperature to constant weight, crushing and sieving to obtain platycodon grandiflorum powder; the method comprises the following steps: simultaneously inoculating pichia pastoris and lipomyces stutzeri into a fermentation culture medium containing platycodon grandiflorum powder and caprylic / capric triglyceride (GTCC), and culturing in a shaking table at constant temperature for 24-48 hours to obtain platycodon grandiflorum fermentation liquor; and sterilizing, layering, centrifuging, dehydrating and adsorbing the platycodon grandiflorum fermentation liquor, and taking an oil phase, namely the platycodon grandiflorum oil fermentation product. The prepared platycodon grandiflorum oil fermentation product has good anti-inflammatory capacity, the anti-inflammatory emulsion prepared from the platycodon grandiflorum oil fermentation product can effectively improve the skin couperose skin phenomenon and remarkably reduce the skin heme content, and the platycodon grandiflorum oil fermentation product can serve as an anti-inflammatory active component in cosmetics and has wide application prospects and remarkable market value.

The present application provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of hereditary hemorrhagic telangiectasia (HHT).

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for treating rosacea, its preparation method, and its application. This invention provides a traditional Chinese medicine composition for treating rosacea, comprising dandelion, purslane, sophora flavescens, sophora japonica flower, and rhubarb. The traditional Chinese medicine composition of this invention has the effects of clearing heat and detoxifying, reducing inflammation and antibacterial properties, cooling blood and promoting blood circulation, and repairing the skin barrier. It can be used to treat erythematous rosacea, relieving erythema, telangiectasia, papules, itching, and burning sensation on the skin, and reducing the risk of recurrence.

The disclosure relates to double stranded ribonucleic acid (dsRNA) agents and compositions targeting the plasminogen (PLG) gene, as well as methods of inhibiting expression of an PLG gene and methods of treating subjects having an PLG-associated disease or disorder, such as hereditary hemorrhagic telangiectasia (HHT), using such dsRNA agents and compositions.

The present disclosure is directed to treating patients with Ataxia-Telangiectasia by administering to the subject at least 5 mg of dexamethasone sodium phosphate (DSP) that has been loaded into erythrocytes. Also disclosed herein are methods of treating a pediatric subject with Ataxia-Telangiectasia who is between 9 and 15 kilograms in weight.

The present invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, for use in the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).

The present invention provides a cell active peptide composition with anti-allergic and redness-reducing effects, its preparation method and medical aesthetic applications, belonging to the fields of medicine and beauty technology. The composition includes: dipeptide-1, tripeptide-1, palmitoyl tripeptide-8, palmitoyl tetrapeptide-7, sh-pentapeptide-1, hydrolyzed silk, mussel extract, dipeptide-2, acetyl tetrapeptide-3, ceramide, 4-tert-butylcyclohexanol, bisabolol, sodium hyaluronate, etc. The composition can repair skin barrier damage; improve skin nerve dysfunction; strengthen immune function and eliminate skin inflammation; enhance the elasticity of the capillary wall and repair telangiectasia. The composition of the present invention is applied to dermatology and skin beauty, can effectively reduce the average value of skin flushing, the area of red area and the redness a value, strengthen the brick-wall structure, has a mild effect, and has the functions of anti-allergic redness reduction, soothing and calming, and immune regulation.

The present disclosure is directed to treating patients with Ataxia-Telangiectasia by administering to the subject at least 5 mg of dexamethasone sodium phosphate (DSP) that has been loaded into erythrocytes. Also disclosed herein are methods of treating a pediatric subject with Ataxia-Telangiectasia who is between 9 and 15 kilograms in weight.